Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Imprimer: 2151-8017
ISSN En ligne: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2014008152
pages 255-273

Venoms Can Be a Boon for Cancer Patients

Sudhir Kumar
IGNOU-I2IT Centre of Excellence for Advanced Education and Research, Pune, Maharashtra, India
Puja Sarkar
IGNOU-I2IT Centre of Excellence for Advanced Education and Research, Pune, Maharashtra, India
Ruchi Jain
Organic Chemistry Division, CSIR National Chemical Laboratory, Pune, Maharashtra, India

RÉSUMÉ

Cancer is one of the leading causes of death worldwide. Remarkable progress has recently been made toward understanding the proposed hallmarks of cancer development and treatment. Treatment modalities comprise radiation therapy, surgery, chemotherapy, immunotherapy, and hormonal therapy. The use of chemotherapeutics currently remains the predominant option for cancer therapy. One of the major problems with successful cancer therapy using chemotherapeutics is that patients often do not respond or eventually develop resistance after initial treatment. This issue has led to the increased use of anticancer drugs developed from natural resources. The biodiversity of venoms and toxins make them a unique source from which new therapeutics may be developed. Some molecules of venom are under clinical trials and may be utilized in anticancer drug development in the near future. This review discusses the anticancer potential of different venoms, surveys the pharmacology of venom peptides, and assesses their therapeutic prospects.


Articles with similar content:

From Molecular Tumor Diagnostics to Individualized Treatment with Phytochemicals Derived from Chinese Herbs
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth
Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine’s Drug Conjugates on Cancer Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 1
Sathish Dyawanapelly, Animesh Kumar, Manish K. Chourasia
Colloidal Carriers: A Rising Tool for Therapy of Tuberculosis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 4
Suresh P. Vyas, Manish K. Gupta, Swati Gupta, Pankaj Kumar
Nanocurcumin: A Promising Therapeutic Advancement over Native Curcumin
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 4
Deepesh Gupta, Archana Tiwari, Gagan Flora
Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Krishna Patel, Maya Nair, Riyaz Basha, Sohail Siraj, Jamboor K. Vishwanatha, Chloe Smith